Pivotal readout
J&J's CAPLYTA succeeds in second Phase 3 trial in bipolar I mania
In Study 452, lumateperone cut YMRS scores by 3.7 points more than placebo at three weeks, and 43.9% of patients responded, compared with 23.7% on placebo. Dizziness, dry mouth and sedation were among the common side effects. With two positive Phase 3 trials, Johnson & Johnson plans to file with the FDA for this use.
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.